Enovis (NYSE:ENOV) Stock Price Expected to Rise, BTIG Research Analyst Says

Enovis (NYSE:ENOV) had its target price upped by research analysts at BTIG Research from $41.00 to $43.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective would indicate a potential upside of 68.70% from the stock’s current price.

ENOV has been the subject of several other reports. Wells Fargo & Company raised their target price on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Evercore restated an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Canaccord Genuity Group dropped their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Wednesday, December 17th. Finally, UBS Group reissued a “buy” rating and set a $50.00 target price on shares of Enovis in a research report on Monday, January 5th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Enovis has a consensus rating of “Moderate Buy” and a consensus target price of $47.43.

Enovis Price Performance

Shares of NYSE:ENOV opened at $25.49 on Thursday. The company has a current ratio of 2.22, a quick ratio of 1.16 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.46 billion, a PE ratio of -1.23 and a beta of 1.52. The stock’s fifty day simple moving average is $24.27 and its two-hundred day simple moving average is $28.19. Enovis has a 1-year low of $21.00 and a 1-year high of $40.69.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 7.91%. The firm had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. During the same quarter in the prior year, the business posted $0.98 EPS. The business’s revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts forecast that Enovis will post 2.79 EPS for the current fiscal year.

Insider Activity

In other news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total value of $27,172.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Enovis

A number of institutional investors have recently added to or reduced their stakes in ENOV. Arax Advisory Partners bought a new position in shares of Enovis in the fourth quarter valued at approximately $29,000. Farther Finance Advisors LLC increased its holdings in shares of Enovis by 42.8% in the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Enovis by 125.4% in the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new stake in Enovis during the second quarter valued at $46,000. Finally, SJS Investment Consulting Inc. grew its position in Enovis by 30,340.0% during the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after buying an additional 1,517 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Adjusted EPS beat — Enovis reported adjusted EPS $0.95 versus consensus ~$0.81, signaling underlying profitability on a non‑GAAP basis. Enovis Q4 2025 Earnings Call Highlights
• Positive Sentiment: Management raised FY2026 adjusted EPS guidance to $3.52–$3.73 (above consensus ~3.35) and expects adjusted EBITDA expansion, providing a clearer path to earnings recovery. Enovis targets $2.31–$2.37B 2026 revenue
• Positive Sentiment: Operational momentum — full‑year 2025 net sales grew ~7% (6% organic) with Reconstructive up ~10% Y/Y; adjusted EBITDA and adjusted EPS for the year improved on a non‑GAAP basis. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Analyst activity supportive — BTIG raised its price target to $43 and keeps a buy stance, signaling some sell‑side confidence in the recovery story. BTIG price target raise
• Neutral Sentiment: Guidance mix — revenue guidance of $2.31–$2.37B implies 4–6% organic growth (positive), but the top‑end sits below some street expectations — a watch item for revenue‑sensitive investors. Guidance detail
• Negative Sentiment: Revenue miss and GAAP impairment — Q4 revenue ~$575.8M missed consensus (~$584M) and the company took a $501M non‑cash goodwill impairment (Q4) that produced a large GAAP loss (Q4 net loss from continuing operations ~$519M), raising concerns about past acquisition valuation and near‑term GAAP volatility. Enovis Misses Q4 Sales Expectations
• Negative Sentiment: Significant non‑cash charges dent headline results — investors focused on GAAP losses and goodwill write‑downs may remain cautious despite positive adjusted metrics. Quiver/summary of results and impairment

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.